BAL 19403

Drug Profile

BAL 19403

Alternative Names: BAL19403

Latest Information Update: 06 Jul 2011

Price : $50

At a glance

  • Originator Basilea Pharmaceutica
  • Class Anti-inflammatories; Antiacnes; Macrolides; Skin disorder therapies
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acne; Bacterial infections

Most Recent Events

  • 01 Oct 2007 Phase-I clinical trials in Bacterial infections in Switzerland (Topical)
  • 01 Oct 2007 Phase-I clinical trials in Acne in Switzerland (Topical)
  • 01 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the adverse events, pharmacokinetics, and Bacterial Infections pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top